Objective-To report the experience, obstacles, and strategies of screening for congenital hypothyroidism.
Neonatal screening programmes for congenital hypothyroidism have become standard in developed countries, but their introduction has been diYcult in Latin America, Asia, and Africa. 1 EVorts were made in 1973 to introduce a universal newborn screening programme for phenylketonuria, homocystinuria, maple syrup urine disease, and tyrosinaemia in Mexico, 2 with congenital hypothyroidism detection included in 1976. However, owing to lack of government support, a further 20 years elapsed before it was extended to all 31 Mexican states and the Federal District. A second pilot study was carried out between 1986 and 1988, 3 and included a cost-benefit analysis. 4 Finally, in 1988 the government made screening mandatory for all Mexican newborns, but only for congenital hypothyroidism. 5 Owing to financial and logistical problems this ruling was first put into eVect for infants born in Mexico City and in two neighbouring states between 1989 and 1993 and then extended to the rest of the nation. National coverage is still incomplete, however, owing to a variety of problems that may be common to other developing countries-for example, (a) the policy of early discharge of most neonates from the maternity hospitals and (b) the fragmented Mexican health sector, resulting in a lack of coordination among the various systems.
Nevertheless, to date, the total number of newborns screened for congenital hypothyroidism has reached one million, and the programme is on the verge of expanding. It is thus a timely moment to present our results and experience for the benefit of similar projects in other countries. Preliminary reports on our data have already been published in Mexican journals. 6 7 
Materials and methods
The infants screened were born at Ministry of Health hospitals in all 31 Mexican states and the Federal District. In most cases blood samples were obtained by heel puncture at the age of 2 to 30 days. Six drops of blood were collected on filter paper (Schleicher and Schuell No 903). In the past two years we have also started to collect samples from the umbilical cord, in order to reduce the number of infants that could not be screened because of an early discharge from hospital. The umbilical cord is clamped by two tweezers and cut in between them; then the tweezer closest to the placenta is released and several drops of blood are collected on the filter paper. The samples are sent by courier to one of six regional laboratories, located in diVerent regions of the country: north in the cities of Monterrey, Tampico, and Torreón; in the centre in Mexico City and León; and south east in Mérida.
Thyroid stimulating hormone (TSH) concentration was measured by enzyme immunoassay using commercial kits (ICN Biomedicals Inc, Costa Mesa, CA). The cut oV value for umbilical cord blood was 40 µU/ml, while for heel blood it was 25 µU/ml. For internal quality control, three blood samples with known TSH concentrations (normal, low, and high) were analysed with each batch. External quality control samples were provided by the Centers for Disease Control, Atlanta. 8 Definitive diagnosis in positive cases was confirmed by measurement of TSH, thyroxine (T4), and triiodothyronine (T3) concentrations in serum. Whenever possible, a thyroid scan with 99 Tc was performed, and bone age was ascertained. Infants with confirmed congenital hypothyroidism were referred for treatment with L-thyroxine.
Results
Between 1 January 1989 and 31 December 1997 1 140 364 infants were screened, most of 1) . In 1997 355 885 infants were screened, representing 87.9% of all those born at the Ministry of Health maternity hospitals during that year, compared with only 5.4% in 1989. The increase in the past two years is due to the sampling of cord blood, which was started in January 1996, and by the end of 1997 was the method used for 39.8% of all samples obtained. The mean time elapsing between birth and the start of replacement treatment of confirmed positive cases was 33.2 days (median 34 days, range 4-58 days).
A total of 1109 samples had TSH concentrations above the cut oV value. Of these, only 735 (66.3%) could be retrieved and restudied. Congenital hypothyroidism was confirmed in 464 infants, indicating an overall prevalence of 1 in 2458 (95% confidence interval 1:2349 to 1:2577. The false positive rate was 0.024% of all infants screened. We found 11 false negative results (1 in 103 636). Congenital hypothyroidism was more common in females (64.4%). Of the 464 cases studied in full, 236 (50.9%) showed ectopic nodular thyroids, 202 (43.5%) thyroid agenesis, 21 (4.5%) dyshormonogenesis, and an unclassifiable goitre was found in the remainder (5) .
Discussion
The incidence of congenital hypothyroidism in Mexico found in the present study is 1 in 2458 live births, somewhat higher than the worldwide prevalence of 1 in 3000 to 1 in 4000. 9 10 The prevalence found in our study is the minimum prevalence because if all neonates with high TSH values (1109) had been recalled, rather than only 735 (see "Results"), it is likely that nearly 700 cases of congenital hypothyroidism, rather than 464, would have been found. The corrected prevalence would thus have been 1 in 1629. We are currently investigating the possible causes of this high prevalence. It may be related to the ethnic background of the Mexican population 11 ; it is noteworthy that in Texas, a disproportionately high number of neonates with congenital hypothyroidism have Spanish surnames, most of them probably of Mexican origin. 12 In some geographical regions the high incidence of congenital hypothyroidism may be associated with iodine deficiency. We are currently analysing the geographical distribution of congenital hypothyroidism. It seems that some of the regions with a high incidence of the disease are those which are iodine deficient. This requires future confirmation.
Although neonatal screening is now carried out in Mexico, the country faces socioeconomic, cultural, logistical, and infrastructural diYculties, many of them similar to those encountered in other developing countries. 1 One important problem has been the early discharge of newborns from maternity hospitals, typically before 24 hours. Samples obtained during the first 24 hours of life should not be tested as the physiological surge of TSH after delivery 13 might greatly increase the false positive results, with concomitant family worries and administrative burden. Early discharge and cost-benefit considerations have discouraged mandatory screening for other conditions, such as phenylketonuria. We have tried diVerent strategies to persuade parents to take infants discharged early to health units to obtain a screening blood sample. The most successful expedient has been providing them with a "comic book", drawn by a popular artist, telling the story of two aVected newborns, only one of whom was screened and thus saved from mental retardation. Nevertheless, only about 50% of the infants discharged early were actually brought back to be screened. For this reason, sampling from cord blood has been gradually introduced during the past two years, resulting in a substantial increase of infants being screened. However, this may cause complications in the future if we wish to add other tests requiring blood drawn later in life.
In Mexico neonatal screening for congenital hypothyroidism has been mandatory for 11 years, but more than half of the newborns are not yet studied. Coverage has been steadily increasing, as described for the Ministry of Health programme (fig 1) , where the current coverage is almost 90%. Health services in Mexico are fragmented in diVerent systems, and newborn screening coverage varies widely among them. The data presented here are only from the Ministry of Health units, covering approximately 30% of the 2 300 000 yearly births in Mexico; these units take care of people without access to social security units or private medical facilities. Therefore, our programme is currently screening about 26% (600 000) of all births in the country. Social security units, covering approximately 40% of births, take care of those with permanent jobs and their families, but started neonatal screening only in 1998, though it is expected that most infants born at these units will be screened by the year 2000. Around 20% of all infants are born at home, attended by midwives; recently, an experimental project was started, training midwives to obtain the screening samples. An additional 10% are born at private hospitals, and it is estimated that about Another barrier to the successful development of congenital hypothyroidism neonatal screening in Mexico, especially in the rural areas, is the limited and tardy recall of those neonates with TSH concentrations above the cut oV values. In some communities up to 60% could not be dealt with locally, and thus the time elapsing between birth and the start of replacement treatment of confirmed positive cases may be as long as two months.
As for most other developing countries, Mexico is socioeconomically heterogeneous and stratified, and its diVerent health systems are embedded in diVerent social, cultural, and economic backgrounds. Most of the above mentioned problems are inextricably related to our country's degree of development, and are compounded by frequent financial plights; it will take time to surmount these diYculties. However, as this and other similar programmes show, a considerable number of infants in developing countries can be spared mental retardation by neonatal screening, and carefully planned strategies can steadily extend its benefits.
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